ABBV vs REGN Stock Comparison: AI Score, Valuation, Performance and Upside
AbbVie and Regeneron are both large biopharmaceutical companies managing significant franchise transitions, with AbbVie having navigated the patent cliff of its former flagship immunology drug through successful newer drug launches, while Regeneron works to diversify beyond its eye disease franchise amid growing competitive pressure.
AbbVie offers exposure to a company that has already substantially navigated its major patent cliff transition through diversified drug launches, while Regeneron offers exposure to a company still working through eye disease franchise competitive pressure while diversifying its pipeline. Consider whether you prefer AbbVie's more advanced transition or Regeneron's ongoing diversification story.
ABBV holds the edge across 3 of 5 key metrics in this comparison. REGN leads on both 1-year return (+51.55%) and forward P/E quality (13.10x vs 15.79x for ABBV), a relatively favorable combination of momentum and valuation. On fundamentals, REGN is growing revenue faster (16.70%), while ABBV maintains the higher operating margin (40.03%) — a classic growth-versus-profitability split. Analyst consensus implies similar upside for both: +7.85% for ABBV and +5.82% for REGN.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a diversified biopharmaceutical company that has successfully navigated a major patent cliff transition
- Believe newer immunology drug launches will continue driving revenue growth
- Value diversification across immunology, oncology, neuroscience, and aesthetics
- Prefer a company further along in its post-patent-cliff transition
- Believe Regeneron's proprietary antibody technology platform will continue generating successful new drugs
- Value diversification into immunology and other therapeutic areas beyond the core eye disease franchise
- Are comfortable with ongoing competitive pressure on the eye disease franchise from biosimilar and alternative treatments
- See upside potential as pipeline diversification efforts progress
| Metric | ABBV | REGN |
|---|---|---|
| AI scorei | 63.0 | 55.3 |
| AI ranki | #178 | #1048 |
| Latest closei | $286.00 | $973.36 |
| 1M returni | +8.82% | +32.39% |
| 3M returni | +17.31% | +27.96% |
| 6M returni | +38.76% | +38.60% |
| 1Y returni | +34.93% | +51.55% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | REGN |
|---|---|---|
| 1Y ago | $13.25K (+32.5%) started 2025-11-04 | $15.5K (+55.0%) started 2025-11-04 |
| 5Y ago | $32.1K (+221.0%) started 2021-11-05 | $15.98K (+59.8%) started 2021-11-05 |
| 10Y ago | $107.58K (+975.8%) started 2016-11-07 | $26.75K (+167.5%) started 2016-11-07 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | REGN |
|---|---|---|
| Market capi | $454.36B | $81.77B |
| Trailing P/Ei | 72.43 | 19.65 |
| Forward P/Ei | 15.79 | 13.10 |
| Price/Salesi | 5.85 | 3.78 |
| EV/Revenuei | 8.06 | 4.76 |
| Analyst targeti | $277.31 | $840.43 |
| Target upsidei | +7.85% | +5.82% |
| Metric | ABBV | REGN |
|---|---|---|
| Revenue growthi | 10.20% | 16.70% |
| Earnings growthi | 290.40% | -4.50% |
| EPS growthi | +290.40% | -4.50% |
| FCF margini | +26.20% | +19.73% |
| Operating margini | 40.03% | 33.11% |
| Profit margini | 9.80% | 27.87% |
| ROIC proxyi | 6225.00% | 14.04% |
| Return on equityi | 6225.00% | 14.04% |
| Dividend yieldi | 2.69% | 0.47% |
| Payout ratioi | 190.40% | 8.18% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.28 | 0.19 |
| Debt/equityi | 4789.60 | 8.54 |
| Current ratioi | 0.81 | 3.33 |
| Quick ratioi | 0.49 | 2.63 |
Over the past year, ABBV and REGN have moved weakly in the same direction (correlation of 0.27), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | REGN |
|---|---|---|---|
| 1Y | Growthi | +32.47% | +54.99% |
| CAGRi | +32.53% | +55.09% | |
| Volatilityi | 25.38% | 36.12% | |
| Sharpe ratioi | 1.08 | 1.29 | |
| Sortino ratioi | 1.67 | 2.20 | |
| Max drawdowni | 16.46% | 26.05% | |
| Current drawdowni | 1.65% | 0.00% | |
| Avg drawdowni | 5.05% | 8.88% | |
| Ulcer Indexi | 6.61% | 11.49% | |
| Max daily dropi | 5.20% | 9.82% | |
| Max wkly dropi | 8.49% | 12.87% | |
| 5Y | Growthi | +178.60% | +59.61% |
| CAGRi | +22.76% | +9.81% | |
| Volatilityi | 23.40% | 32.06% | |
| Sharpe ratioi | 0.81 | 0.31 | |
| Sortino ratioi | 1.13 | 0.46 | |
| Max drawdowni | 21.92% | 59.69% | |
| Current drawdowni | 1.65% | 18.78% | |
| Avg drawdowni | 8.04% | 20.84% | |
| Ulcer Indexi | 9.99% | 28.45% | |
| Max daily dropi | 12.57% | 19.01% | |
| Max wkly dropi | 17.30% | 20.21% | |
| 10Y | Growthi | +597.33% | +167.13% |
| CAGRi | +21.46% | +10.33% | |
| Volatilityi | 25.92% | 32.63% | |
| Sharpe ratioi | 0.71 | 0.33 | |
| Sortino ratioi | 0.99 | 0.49 | |
| Max drawdowni | 45.09% | 59.69% | |
| Current drawdowni | 1.65% | 18.78% | |
| Avg drawdowni | 11.47% | 21.65% | |
| Ulcer Indexi | 15.56% | 27.15% | |
| Max daily dropi | 16.25% | 19.01% | |
| Max wkly dropi | 19.39% | 20.21% |
| Category | ABBV | REGN |
|---|---|---|
| Company | AbbVie Inc. | Regeneron Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | A biopharmaceutical company with a diversified portfolio spanning immunology, oncology, neuroscience, and aesthetics, having successfully transitioned its revenue base following the loss of patent exclusivity on its former flagship immunology drug. | A biotechnology company known for its eye disease treatment franchise, alongside a growing portfolio of immunology, oncology, and other therapeutic treatments developed using its proprietary antibody technology platform. |
| Investor focus | Newer immunology drug growth trends replacing the prior flagship treatment, oncology and neuroscience pipeline contributions, and overall revenue diversification progress. | Eye disease franchise competitive dynamics amid biosimilar and alternative treatment competition, newer drug pipeline contributions, and overall revenue diversification pace. |
- Successfully launched newer immunology drugs that have replaced much of the revenue lost from prior patent expiration
- Diversified therapeutic area exposure spans immunology, oncology, neuroscience, and aesthetics, reducing reliance on any single franchise
- Strong commercial execution track record in immunology provides confidence in continued drug launch and market penetration capabilities
- Proprietary antibody technology platform has supported a strong track record of successful drug discovery and development
- Growing immunology and other therapeutic area drugs provide diversification beyond the core eye disease franchise
- Established commercial infrastructure and physician relationships support new product launch execution
- Continued reliance on successful execution of newer immunology drug launches to fully offset prior patent cliff impact
- Competitive immunology therapeutic landscape includes numerous other well-resourced biopharmaceutical companies
- Aesthetics segment demand can be more discretionary and sensitive to broader consumer spending conditions
- Core eye disease franchise faces increasing competitive pressure from biosimilar and alternative treatment options
- Revenue diversification into newer therapeutic areas requires sustained successful clinical and commercial execution
- Competitive biopharmaceutical landscape across immunology and other pursued therapeutic areas includes numerous large competitors
Compare more than two at a time
This page is a fixed writeup on ABBV and REGN. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ABBV and REGN, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.